

Accepted Manuscript

Angubindin-1 opens the blood–brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system

Satoshi Zeniya, Hiroya Kuwahara, Kaiichi Daizo, Akihiro Watari, Masuo Kondoh, Kie Yoshida-Tanaka, Hidetoshi Kaburagi, Ken Asada, Tetsuya Nagata, Masahiro Nagahama, Kiyohito Yagi, Takanori Yokota



PII: S0168-3659(18)30267-0
DOI: doi:[10.1016/j.jconrel.2018.05.010](https://doi.org/10.1016/j.jconrel.2018.05.010)
Reference: COREL 9292
To appear in: *Journal of Controlled Release*
Received date: 23 October 2017
Revised date: 4 May 2018
Accepted date: 10 May 2018

Please cite this article as: Satoshi Zeniya, Hiroya Kuwahara, Kaiichi Daizo, Akihiro Watari, Masuo Kondoh, Kie Yoshida-Tanaka, Hidetoshi Kaburagi, Ken Asada, Tetsuya Nagata, Masahiro Nagahama, Kiyohito Yagi, Takanori Yokota , Angubindin-1 opens the blood–brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Corel(2017), doi:[10.1016/j.jconrel.2018.05.010](https://doi.org/10.1016/j.jconrel.2018.05.010)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Angubindin-1 opens the blood–brain barrier *in vivo* for delivery of antisense oligonucleotide to the central nervous system

Satoshi Zeniya^{a,b, 1}, Hiroya Kuwahara^{a,b,1}, Kaichi Daizo^{a,b}, Akihiro Watari^c, Masuo Kondoh^c, Kie Yoshida-Tanaka^{a,b}, Hidetoshi Kaburagi^d, Ken Asada^{a,b}, Tetsuya Nagata^{a,b}, Masahiro Nagahama^e, Kiyohito Yagi^c, and Takanori Yokota^{a,b,*} tak-yokota.nuro@tmd.ac.jp

^aDepartment of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Address: 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

^bCenter for Brain Integration Research, Tokyo Medical and Dental University (TMDU), Address: 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

^cGraduate School of Pharmaceutical Sciences, Osaka University, Address: 1-6, Yamadaoka, Suita, Osaka 565-0871, Japan

^dDepartment of Orthopaedic and Spinal Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Address: 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

^eDepartment of Microbiology, Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770-8514, Japan.

*Corresponding author.

Abstract

Within the field of RNA therapeutics, antisense oligonucleotide-based therapeutics are a potentially powerful means of treating intractable diseases. However, if these therapeutics are used for the treatment of neurological disorders, safe yet efficient methods of delivering antisense oligonucleotides across the blood–brain barrier to the central nervous

¹ These authors contributed equally to this work.

Download English Version:

<https://daneshyari.com/en/article/7859455>

Download Persian Version:

<https://daneshyari.com/article/7859455>

[Daneshyari.com](https://daneshyari.com)